Avoiding toxicity with lung radiation therapy: An IASLC perspective
AuthorsBucknell, N. W.
Palma, D. A.
Louie, A. V.
Hanna, G. G.
AffiliationDepartment of Radiation Oncology, Sir Charles Gardiner Hospital, Perth, Australia
MetadataShow full item record
AbstractToxicity concerns from thoracic radiation therapy in the treatment of lung cancers have changed substantially over the past few decades. Survival in the treatment of lung cancer has markedly improved and the introduction of advanced radiation and imaging techniques to treatment planning and delivery has made reducing toxicity possible. Phase 3 dose-escalation trials have revealed that excess dose to critical organs within the thorax can negatively impact overall survival. We summarize the existing literature on the known toxicities of thoracic radiation therapy, summarize the technological advances that have made toxicity reduction possible, and provide an overview of emerging technologies and biomarkers that are being evaluated to assess future toxicity reductions.
CitationBucknell NW, Belderbos J, Palma DA, Iyengar P, Samson P, Chua K, et al. Avoiding Toxicity With Lung Radiation Therapy: An IASLC Perspective. Journal of Thoracic Oncology. Elsevier BV; 2022.
JournalJournal of Thoracic Oncology
- Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.
- Authors: Reboul FL
- Issue date: 2004 Feb
- Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy in locally advanced non-small cell lung cancer: analysis of early and late pulmonary morbidity.
- Authors: Robert F, Childs HA, Spencer SA, Redden DT, Hawkins MM
- Issue date: 1999 Apr
- Response, toxicity, failure patterns, and survival in five Radiation Therapy Oncology Group (RTOG) trials of sequential and/or concurrent chemotherapy and radiotherapy for locally advanced non-small-cell carcinoma of the lung.
- Authors: Byhardt RW, Scott C, Sause WT, Emami B, Komaki R, Fisher B, Lee JS, Lawton C
- Issue date: 1998 Oct 1
- Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
- Authors: Higgins KA, Pillai RN, Chen Z, Tian S, Zhang C, Patel P, Pakkala S, Shelton J, Force SD, Fernandez FG, Steuer CE, Owonikoko TK, Ramalingam SS, Bradley JD, Curran WJ
- Issue date: 2017 Nov
- Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers.
- Authors: Dowell JE, Sinard R, Yardley DA, Aviles V, Machtay M, Weber RS, Weinstein GS, Chalian AA, Carbone DP, Rosenthal DI
- Issue date: 1999 Apr